Colorectal cancer (CRC) screening disparities are a stark reality, especially for Black adults. But what if there was a more accessible and cost-effective option? Researchers are pointing to CT colonography (CTC) as a potential game-changer, particularly in addressing the deep-seated inequalities in CRC screening. Let's dive into the details.
A recent study published in Cancer Medicine suggests that CTC could be a cost-effective and readily available method for CRC screening specifically within the Black community. This is crucial because, as researchers like Szu-Yu Zoe Kao, PhD, from Siemens Medical Solutions USA and her colleagues at the Harvey L. Neiman Health Policy Institute (HPI) point out, it could pave the way for broader Medicare coverage of CTC screening. This, in turn, could directly address the unique needs and barriers that often prevent Black adults from getting screened.
CRC is a major health concern in the U.S., with estimated treatment costs soaring to $26 billion by 2025. Early detection through screening is key to preventing the disease by identifying precancerous polyps. Current screening methods include colonoscopy, CTC, and various stool-based tests, with colonoscopy being the most frequently used approach. But here's where it gets controversial...
Despite overall declines in CRC incidence, Black adults continue to experience higher rates of the disease compared to their white counterparts. The researchers attribute this disparity to differences in "screening access, utilization, and test preference." Specifically, Black individuals tend to opt for stool-based tests more often, while white adults favor colonoscopy. And this is the part most people miss...
Kao and her team suggest that these differences aren't simply a matter of personal choice. Instead, "structural barriers" play a significant role. These barriers can include a lack of adequate insurance coverage, limited recommendations from healthcare providers, and infrequent visits to primary care physicians – all of which can restrict access to colonoscopies for Black populations.
CTC offers a compelling alternative. It's more effective at detecting colorectal adenomas (precancerous growths) than stool-based tests and provides cancer detection rates comparable to colonoscopy. Even more promising, studies show that Black individuals exhibit a "greater willingness to undergo CTC than white adults," highlighting its potential to narrow racial disparities in screening while maintaining high-quality detection. The accessibility of CTC also received a boost in January when the U.S. Centers for Medicare and Medicaid Services (CMS) began covering it as a screening test.
To evaluate the cost-effectiveness of CTC, the researchers developed a sophisticated microsimulation model. This model compared various CRC screening strategies in average-risk adults, broken down by race and gender. They used U.S. data from 2010 to 2019, incorporating information on disease progression and real-world adherence rates for colonoscopy and fecal immunochemical testing (FIT). The model compared five different screening strategies:
- Status Quo: Patients choose between colonoscopy and FIT.
- CTC Every 5 Years: All participants undergo CTC every five years.
- Colonoscopy Every 10 Years: All participants undergo colonoscopy every ten years.
- Annual FIT: All participants undergo FIT annually.
- Multitarget Stool DNA Test Every 3 Years: All participants undergo a multitarget stool DNA test every three years, with no other screening.
The team then evaluated lifetime costs, quality-adjusted life years gained (QALYG), and incremental cost-effectiveness ratios, using a willingness-to-pay threshold of $100,000 per QALYG. Boldly highlighting any point in the article that could spark differing opinions.
The key finding was that, compared to the status quo, the CTC-only strategy resulted in more QALYG and fewer CRC cases among Black adults. Interestingly, this strategy resulted in fewer QALYG and more CRC cases among white adults. The research also showed that, under the status quo, Black adults had higher CRC rates and were more likely to use FIT than colonoscopy, compared to white adults. The status quo and CTC strategies generally outperformed the other strategies across all races.
In conclusion, the researchers stated that "Analysis of real-world screening adherence shows the CTC-only strategy emerged as the dominant strategy for Black adults, while both the CTC-only and status quo strategies could be optimal for white adults depending on resource constraints... These racial differences stemmed primarily from disparities in screening adherence in the status quo strategy." This suggests that offering CTC as a readily available option could significantly improve CRC screening rates and outcomes for Black adults.
What are your thoughts on these findings? Do you believe CTC can truly bridge the gap in CRC screening disparities? And how can we ensure equitable access to this potentially life-saving screening method for all communities? Share your opinions and experiences in the comments below! You can find the full study here: https://dx.doi.org/10.1002/cam4.71290
